Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
10.05.2022 - New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical ...
United States Jean Pierre Sommadossi Jonae Barnes Founder Of Atea Pharmaceuticals Bemnifosbuvir Clinical Development Nature Communications
Source: wallstreet-online.de